The brain scan, made possible with a new generation of radioactive pharmaceuticals, brings researchers a step closer to understanding chronic traumatic encephalopathy, or CTE. {read more here}

Scientists at Lawson Health Research Institute are the first in Canada to capture prostate cancer images using a new molecule. Known as a Prostate Specific Membrane Antigen (PSMA) probe, the new molecule is used in Positron Emissions Tomography (PET) scans. The probe targets PSMA, a unique molecule on prostate cancer cells, to provide highly specific images for better diagnosis and management of patient disease. {read more here}

A drug designed to fight triple negative breast cancer already shows promising results.  A new development in drug design could pave the way for a new generation of drugs that could be used to treat a range of diseases. By precisely targeting genes and sequences that allow diseases to proliferate, the researchers believe that they can stop or slow their progression to make them more manageable. {read more here}

In a new study, researchers found images of tau tangles in the brain were more closely related to a person’s cognitive function than images of a second, more widely studied protein called beta amyloid. The technology that makes that possible could help diagnose patients and determine best course of treatment down the line. {read more here}